| Literature DB >> 34213728 |
Rahman Abdizadeh1, Farzin Hadizadeh2, Tooba Abdizadeh3.
Abstract
Coronavirus disease 2019 (COVID-19) is a pandemic viral disease caused by SARS-CoV-2 that generated serious damages for both the human population and the global economy. Therefore, it is currently considered as one of the most important global health problems of human societies and there is an urgent need for potent drugs or vaccines which can effectively combat this virus. The chymotrypsin-like protease (3CLpro) of SARS-CoV-2 plays a key role in the viral replication inside the host and thus is a promising drug target to design and develop effective antiviral drugs against SARS and other coronaviruses. This study evaluated some antiviral coumarin phytochemicals as potential inhibitors of coronaviruses 3CLpro by in silico approaches such as molecular docking, ADMET prediction, molecular dynamics simulation, and MM-PBSA binding energy calculation. Natural coumarin derivatives were docked to the 3CLpro of SARS-CoV-2 and for further investigation, docked to the 3CLpro of SARS-CoV and MERS-CoV. The docking scores of these natural compounds were compared with 3CLpro referenced inhibitors (ritonavir and lopinavir) and co-crystal inhibitor N3. Molecular docking studies suggested more than half of the coumarin phytochemicals had favorable interaction at the binding pocket of the coronaviruses 3CLpro and exhibited better binding affinities toward 3CLpro than ritonavir and lopinavir. Most antiviral phytochemicals interact strongly with one or both the catalytic dyad residues (His41 and Cys145) and the other key residues of SARS-CoV-2 main protease. Further, MD simulation and binding free energy calculations using MM-PBSA were carried out for three 3CLpro-coumarin complexes and 3CLpro-N3/lopinavir. The results confirmed that the 3CLpro-glycycoumarin, 3CLpro-oxypeucedanin hydrate, and 3CLpro-inophyllum P complexes were highly stable, experience fewer conformation fluctuations and share a similar degree of compactness. Also, the pharmacokinetics and drug-likeness studies showed good results for the selected coumarin phytochemicals.Therefore, the coumarin phytochemicals could be used as antiviral agents in the treatment of COVID-19 after further studies.Entities:
Keywords: COVID-19; Coumarin phytochemicals; Molecular docking; Molecular dynamics; SARS-CoV-2
Mesh:
Substances:
Year: 2021 PMID: 34213728 PMCID: PMC8251691 DOI: 10.1007/s11030-021-10230-6
Source DB: PubMed Journal: Mol Divers ISSN: 1381-1991 Impact factor: 3.364
Fig. 1Schematic representation of various steps of the methodology to identify the phytochemical based coumarin inhibitors of 3CLpro
Fig. 2Frequency distribution of 50 coumarin phytochemicals over the range of docking scores
Interacting amino acid (aa) residues of 3CLpro of coronaviruses with the best coumarin phytochemicals
| Bioactive compound | Coronavirus | Interacted residues | aa residue involved in H-bonding (Bond Distance) |
|---|---|---|---|
| Ritonavir | SARS-CoV-2 | His 41, Cys145, Gly143, Met165, His164, Glu166, Asn142, Met49, Gln189, Thr26, Thr24, Thr25, Thr45, Ser46 | Glu166 (2.48), Thr25 (3.72) |
| Lopinavir | His 41, Cys145, Gly143, Met165, His164, Glu166, Asn142, Leu141, Phe140, Met49, Gln189, Asp187 | Gln189 (2.08) | |
| Glycycoumarin | His 41, Cys145, Ser144, Gly143, Met165, His164, Glu166, Asn142, Leu141, Phe140, Met49, Gln189, Asp187, Arg188, Tyr54 | Cys145 (2.46), Ser144 (1.91), Gln189 (2.15) | |
| Inophyllum P | His 41, Cys145, Ser144, Gly143, Met165, His164, Glu166, Asn142, Leu141, Phe140, Met49, Gln189, Leu27 | Cys145 (2.607), Ser144 (2.23), Leu141 (3.18) | |
| Mesuol | His 41, Cys145, Ser144, Gly143, Met165, His164, Glu166, Asn142, Leu141, Phe140, Met49, Gln189, Ser46 | Cys145 (2.608), Ser144 (3.77), Asn142 (1.27) | |
| Oxypeucedanin hydrate | His 41, Cys145, Ser144, Gly143, Met165, His164, Glu166, Asn142, Leu141, Phe140, Met49, Gln189, His163, Thr25, Thr26, Leu27 | Cys145 (3.04), Ser144 (2.21), His163 (2.86), His164 (3.04) | |
| Glycycoumarin | SARS-CoV | Gln189, Met165, His164, Cys145, His41, Arg188, Asp48, Cys44, Thr25, Glu47, Thr24, Thr45, Ala46 | His164 (2.41), Cys44 (2.51), Thr24 (2.30) |
| Inophyllum G2 | Gln189, Met165, His164, Cys145, His41, Arg188, Asp48, Cys44, Glu47, His163, Glu166, Met49, Asn142, Leu27, Thr26 | His164 (2.862), Glu166 (3.09), Asn142 (2.47) | |
| licopyranocoumarin | Phe140, Met165, His164, Cys145, His41, Ser144, Asp48, Cys44, Glu47, His163, Glu166, Met49, Asn142, Leu25, Thr24, Asp48, His172 | His163 (2.35), Thr25 (2.29, thr45 (3.72) | |
| Wedelolactone | Phe140, Met165, His164, Cys145, His41, Ser144, Asp48, Glu47, His163, Glu166, Met49, Asn142, His172, Leu141, Gly143 | Glu166 (2.07), Ser144 (1.72), Leu141 (2.02) | |
| Glycycoumarin | MERS-CoV | Met6, Asp294, Gln299, Asp295, Met298, Asn156, Glu157, Glu155 | Met6 (2.21), Asp295 (2.16), Asn156 (1.93) |
| licopyranocoumarin | Met6, Asp294, Gln299, Asp295, Met298, Asn156, Glu157, Glu155, Thr13, Lys5, Phe291, Ala8, Ser7, | Gln299 (1.790), Asn156 (3.58), Gly157 (3.21) | |
| Wedelolactone | Met6, Asp294, Gln299, Asp295, Met298, Asn156, Glu157, Glu155, Thr130, Phe291, Ala8, Phe115, Ser116, Thr154, | Glu155 (2.56), ser116 (2.48), Thr130 (3.22), Asp295 (2.84) | |
| Isomesuol | Met6, Asp294, Gln299, Asp295, Met298, Asn156, Glu157, Glu155, Ala8, Thr154, Ser116, Tyr153, Phe115, Phe291 | Gln299 (3.14), Ser114 (3.09) |
Fig. 32D view of the binding conformation of ligands in binding pocket of SARS-CoV-2 3CLpro, a Ritonavir, b Lopinavir, c Glycycoumarin, d Inophyllum P, e Mesuol, f Oxypeucedanin hydrate
Fig. 42D representation of 3CLpro amino acid interactions of SARS-CoV with coumarin phytochemicals; a glycycoumarin, b licopyranocoumarin, c Inophyllum G2, d wedelolactone
Fig. 52D representation of 3CLpro amino acid interactions of MERS-CoV with coumarin phytochemicals; a Glycycoumarin, b Licopyranocoumarin, c Wedelolactone and d Isomesuol
In Silico ADME/T prediction of the top binding coumarin phytochemicals
| Compound | Absorption | Distribution | Metabolism | Excretion | Toxicity | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Water solubility | Intestinal absorption (human) | Blood brain barrier Permeability | VDss (human) | CYP | Total Clearance | AMES toxicity | |||||||
| 2D6 | 3A4 | 1A2 | 2C19 | 2C9 | 2D6 | 3A4 | |||||||
| substrate | inhibitor | ||||||||||||
| (logmol/L) | Numeric (%Absorbed) | (log BB) | (log (L/kg) | Categorical | (Yes/No) | Numeric (log ml/min/kg) | (Yes/No) | ||||||
| glycycoumarin | -4.08 | 88.20 | -1.14 | -0.28 | No | No | Yes | Yes | Yes | No | Yes | 0.78 | Yes |
| Inophyllum P | -5.08 | 96.48 | -0.43 | 0.32 | No | Yes | Yes | Yes | Yes | No | Yes | 0.56 | Yes |
| Mesuol | -5.41 | 96.68 | -0.10 | -0.05 | No | Yes | Yes | Yes | Yes | No | Yes | 0.80 | Yes |
| Oxypeucedanin hydrate | -3.09 | 97.44 | -0.66 | 0.33 | No | No | Yes | No | No | No | No | 0.75 | No |
Drug likeness properties of the top binding coumarin phytochemicals
| Drug Likeness Properties | Glycycoumarin | Inophyllum P | Mesuol | Oxypeucedanin hydrate |
|---|---|---|---|---|
| Molecular weight (g/mol)a | 368.38 | 404.46 | 392.44 | 304.29 |
| Consensus Log | 3.54 | 4.14 | 4.56 | 1.79 |
| Log Sc | − 5.06 | − 5.28 | − 5.87 | − 2.69 |
| Num. H-bond acceptord | 6 | 5 | 5 | 6 |
| Num. H-bond donore | 3 | 1 | 2 | 2 |
| No of Rotatable Bondsf | 4 | 1 | 5 | 4 |
| Molar Refractivity | 104.20 | 116.97 | 115.49 | 80.34 |
| Lipinski | Yes | Yes | Yes | Yes |
| Ghose | Yes | Yes | Yes | Yes |
| Veber | Yes | Yes | Yes | Yes |
| Egan | Yes | Yes | Yes | Yes |
| Muegge | Yes | Yes | No | Yes |
| Bioavailability score | 0.55 | 0.55 | 0.55 | 0.55 |
| TPSA (A2)g | 100.13 | 68.90 | 87.74 | 93.04 |
| Synthetic accessibility (SA) | 3.55 | 5.12 | 3.88 | 3.79 |
| Solubility (mol/l) | 1.79e-06 | 5.20e06 | 1.36e06 | 2.05e03 |
| PAINSh | 0 alert | 0 alert | 0 alert | 0 alert |
| Brenkj | 2 alert | 1 alert | 2 alert | 1 alert |
| Leadlikeness | No | No | No | Yes |
The general recommended ranges are as follows:
aMolecular weight, < 500
bPredictedoctanol/water partition coefficient, − 0.4 to + 5.6
cPredicted aqueous solubility, < -5.0
dNumber of hydrogen bond acceptors, < 10
eNumber of hydrogen bond donor, < 5
fRotatable bonds, < 10
gPolar surface area, < 140 A°2
hPan-Assay Interference
jStructural Alert
The PASS prediction results of the biological activities of the coumarin phytochemicals series
| No | Biological activities | Glycycoumarin | Inophyllum P | Mesuol | Oxypeucedanin hydrate | ||||
|---|---|---|---|---|---|---|---|---|---|
| Pa | Pi | Pa | Pi | Pa | Pi | Pa | Pi | ||
| 1 | Membrane integrity agonist | 0.937 | 0.002 | – | – | 0.683 | 0.058 | 0.720 | 0.051 |
| 2 | HMOX1 expression enhancer | 0.635 | 0.015 | – | – | 0.265 | 0.115 | 0.355 | 0.072 |
| 3 | Chlordeconereductase inhibitor | 0.803 | 0.02 | – | – | 0.243 | 0.193 | 0.344 | 0.132 |
| 4 | HIF1A expression inhibitor | 0.936 | 0.004 | 0.867 | 0.008 | 0.348 | 0.135 | 0.512 | 0.053 |
| 5 | Histidine kinase inhibitor | 0.709 | 0.008 | 0.765 | 0.005 | 0.467 | 0.035 | 0.498 | 0.029 |
| 6 | Aldehyde oxidase inhibitor | 0.807 | 0.009 | – | – | – | – | 0.654 | 0.023 |
| 7 | Antimutagenic | 0.877 | 0.003 | – | – | – | – | 0.735 | 0.005 |
| 8 | Mucomembranous protector | 0.648 | 0.081 | – | – | 0.307 | 0.234 | – | – |
| 9 | TP53 expression enhancer | 0.901 | 0.005 | 0.484 | 0.098 | 0.616 | 0.045 | 0.580 | 0.056 |
| 10 | Chemopreventive | 0.807 | 0.004 | 0.665 | 0.008 | 0.615 | 0.009 | 0.596 | 0.010 |
Pa: prediction of activity spectra for substances; Pi: probable inactivity
List of the P450 sites of metabolism prediction study of the Glycycoumarin, Oxypeucedanin hydrate Inophyllum P and Mesoul molecules
Fig. 6Top-25 of target predicted for a Glycycoumarin, b Oxypeucedanin hydrate, c Inophyllum P and d Mesuol
Fig. 7Pharmacophore Mapping of glycycoumarin in the binding site of 3CLpro. Cyan color-hydrogen bond acceptor, orange color-aromatic, dark pink color- hydrogen bond acceptor and donor
Fig. 8RMSD plots of ligand free 3CLpro, 3CLpro-N3, 3CLpro-lopinavir, 3CLpro-glycycoumarin, 3CLpro-oxypeucedanin hydrate, and 3CLpro-Inophyllum P complexes of SARS-CoV-2
Fig. 9RMSF plot of ligand free 3CLpro and the 3CLpro-ligand complexes of SARS-CoV-2
Fig. 10Total number of H-bond count throughout the simulation for ligand free 3CLpro and the 3CLpro-ligand complexes of SARS-CoV-2
Fig. 11Number of intermolecular hydrogen bonds between 3CLpro of SARS-CoV-2 and N3, glycycoumarin, oxypeucedanin hydrate, Inophyllum P and lopinavir
Fig. 12Radius of gyration (Rg) plot ligand free 3CLpro and the 3CLpro-ligand complexes of SARS-CoV-2
Fig. 13Solvent accessible surface area (SASA) plot ligand free 3CLpro and the 3CLpro-ligand complexes of SARS-CoV-2
Binding free energy for glycycoumarin, oxypeucedanin hydrate and Inophyllum P and 3CLpro of SARS-CoV-2 calculated by MM-PBSA analysis
| Complex | Van der Waal energy (ΔEvdW) (Kj/mol) | Electrostatic energy (ΔEelec) (Kj/mol) | Polar solvation energy (ΔG polar) (Kj/mol) | SASA energy (Kj/mol) | Binding energy (Kj/mol) |
|---|---|---|---|---|---|
| 3CLpro-N3 | − 51.67 | − 45.39 | 54.58 | − 13.77 | − 56.25 |
| 3CLpro-Lopinavir | − 33.24 | − 38.83 | 43.76 | − 12.63 | − 40.94 |
| 3CLpro-glycycoumarin | − 44.16 | − 58.58 | 58.59 | − 16.15 | − 60.31 |
| 3CLpro-Oxypeucedanin hydrate | − 48.97 | − 53.79 | 63.13 | − 19.23 | − 58.86 |
| 3CLpro-Inophyllum P | − 53.48 | − 45.78 | 56.49 | − 14.97 | − 57.75 |
Fig. 14binding free energies of the residues which have considerable interactions with N3, Lopinavir, glycycoumarin, Oxypeucedanin hydrate and Inophyllum P
Fig. 15Superposition of molecular docking result and MD structure of compound glycycoumarin with 3CLpro after 50 ns simulations. The residues of active site (pink), docked glycycoumarin (dark cyan) and MD glycycoumarin (olive drab)